/ Glenmark Gets USFDA Approval For Capsules Treating Leukemia Stocks Up 1.2% ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 4 January 2017

Pharma major Glenmark Pharmaceuticals has received final approval from the US health regulator USFDA for sale of Tretinoin Capsules, used in treatment of leukemia. Glenmark Pharmaceuticals Ltd is currently trading at Rs 904.6, up by Rs 10.85 or 1.21% from its previous closing of Rs 893.75 on the BSE.

The scrip opened at Rs 905 and has touched a high and low of Rs 912.9 and Rs 902.45 respectively. So far 397298(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 25218.78 crore.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 993 on 01-Nov-2016 and a 52 week low of Rs 671.5 on 12-Feb-2016. Last one week high and low of the scrip stood at Rs 932.8 and Rs 881 respectively.

The promoters holding in the company stood at 46.49 % while Institutions and Non-Institutions held 41.61 % and 11.91 % respectively. The stock is currently trading above its 50 DMA.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717